SpyGlass Pharma, Inc. Common Stock
SGPHealthcare|Biotechnology|US
$36.95
+2.87 (+8.41%)
DCF Value
$2.90
Tangible Book / Share
$6.95
Cash / Share
$7.00
About
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
Stock Price
+40.0%(1Y)
1M
+50.1%
3M
+46.0%
6M
+57.8%
YTD
+39.9%
1Y
+39.9%
3Y
+39.9%
5Y
+39.9%
Pipeline Summary
0 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Key Facts
Market Cap$1.24B
Employees65
CEOPatrick H. Mooney
IPO DateFeb 6, 2026
Beta-0.89
52-Week Range$17.06 – $37.12
Avg Volume109,197
ExchangeNASDAQ
Websitespyglasspharma.com
Ownership
Float41.8%
Shares Outstanding33.4M
Peers
Recent News
SpyGlass Pharma to Participate in Upcoming Investor Conferences
Nov 5, 2026 · globenewswire.com
SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System
Oct 19, 2026 · globenewswire.com
EdgeConneX Enters Australia in Partnership with Stockland, with Hyperscale Data Center Campuses Planned in Sydney and Melbourne
Oct 14, 2026 · businesswire.com
SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability
Oct 1, 2026 · globenewswire.com
SpyGlass Pharma, Inc. (SGP) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Sep 10, 2026 · seekingalpha.com
Data last updated: Nov 9, 2026, 04:33 AM